Insmed Incorporated (NASDAQ:INSM – Get Free Report) insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the transaction, the insider now owns 100,100 shares of the company’s stock, valued at $7,157,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Insmed Stock Performance
Shares of NASDAQ INSM opened at $71.57 on Wednesday. The company has a 50 day simple moving average of $73.96 and a two-hundred day simple moving average of $49.34. The stock has a market cap of $12.30 billion, a price-to-earnings ratio of -13.74 and a beta of 1.11. The company has a current ratio of 2.71, a quick ratio of 2.53 and a debt-to-equity ratio of 25.05. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53.
Insmed (NASDAQ:INSM – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The firm had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. The firm’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same period in the previous year, the business posted ($1.78) earnings per share. As a group, analysts predict that Insmed Incorporated will post -5.42 earnings per share for the current year.
Institutional Investors Weigh In On Insmed
Wall Street Analyst Weigh In
INSM has been the subject of several recent analyst reports. Truist Financial reduced their price objective on shares of Insmed from $88.00 to $85.00 and set a “buy” rating for the company in a research note on Monday, August 12th. The Goldman Sachs Group raised their price objective on Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a research report on Wednesday, July 10th. TD Cowen boosted their target price on Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Stifel Nicolaus increased their price target on Insmed from $74.00 to $88.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Guggenheim boosted their price target on Insmed from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $79.19.
Read Our Latest Report on Insmed
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Stories
- Five stocks we like better than Insmed
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- How to Use the MarketBeat Excel Dividend Calculator
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.